Results for 'rupi kaur'

Topical Dermal Drug Delivery

Dr. Jitender Madan is Associate Professor and Head of the Department of Pharmaceutics at NIPER Hyderabad, a leading researcher and educator in pharmaceutical sciences. His research centers on self-assembled supramolecular systems—liposomes, niosomes, cyclodextrins, nano- and microparticles, and solid-lipid nanoparticles—and leverages FDA-approved biomaterials with lipids and polymers to develop innovative dosage forms that improve bioavailability, stability, safety, and patient compliance. He has mentored numerous doctoral and postgraduate scholars and led industry collaborations and government-funded projects. Notable products include cycloencapsulated andrographolide for immune support and a veterinary spray for bovine mastitis. He has authored a robust body of peer-reviewed papers and book chapters, holds several patents, and has edited nanotechnology-focused volumes. A recognized educator and researcher, he actively contributes as a peer reviewer and advances pharmaceutical science and education through programs like SRIP. Whilst a wide range of applications are being taken up, the special emphasis is given to augment the aqueous solubility and bioavailability of lipophilic drugs. Dr. Tathagata Dutta has earned his M.Pharm and PhD in Pharmaceutical Sciences from Dr. Hari Singh Gour University, Sagar and completed his postdoctoral studies from School of Pharmacy & Diamantina Institute for cancer, Immunology and Metabolic Medicine, University of Queensland, Brisbane, Australia and was engaged in development of RNAi therapeutics for effective management of cancer. He has served as Chief Scientific Officer (CSO), Vice President (R&D), Executive Director, Managing Director & CEO of several reputed Multinational Pharmaceutical Companies for more than two decades. He is the editorial board member of several international journals on drug discovery & delivery research. His research interests include novel drug delivery systems, dendrimers, liposomes, polymer bioconjugates, tissue targeted drug delivery systems, nano drug delivery systems, gene therapy, genetic immunization, depot injections, gene delivery, and development of RNAi therapeutics. Presently, he is the Chief Technology Officer (CTO) of JODAS EXPOIM Pvt Ltd. Dr. Sodhi has a doctorate in pharmacology with more than 14 years of experience in guiding the postgraduate students for scientific projects in an academic setting. While teaching, he strongly emphasizes the use of bioinformatics tools for literature survey, formulation of hypothesis, and guide students to publish their research work in peer reviewed journals. I am also delivering lessons to postgraduate students in drug evaluation techniques and animal models used in experimental pharmacology. He is a Coordinator/ Member Secretary for Institutional animal’s ethical committee (IAEC) for the conduct of the meetings for the approval of experimental animals. He is actively engaged in maintaining the animal house facilities per the norms. Dr. Ravi Shankar Pandey is presently a Professor in the Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur C.G. India. He has authored two book chapters in international publishers. He has published more than 44 research papers in reputed peer-reviewed journals. He has presented many papers and participated as a resource person in International and National conferences. He has guided three PhD students, and four research scholars are doing research under his guidance. He is a reviewer of various international journals. He has 21 years of teaching experience in undergraduate and postgraduate pharmacy courses with more than 14 years of research experience. He has guided several undergraduate and postgraduate students in their project work. Moreover, as a guest PhD student, he worked at the University of Copenhagen, Denmark. He is a life member of professional bodies such as the Indian Science Congress and the Association of Pharmaceutical Teachers of India. He is a registered pharmacist at the State Pharmacy Council of Chhattisgarh, India. He has received grants from the University Grants Commission New Delhi and the Indian Council of Medical Research New Delhi for research in vaccine and protein drug delivery. Prof. Ramesh Chandra is a distinguished scientist and Fellow of the Royal Society of Chemistry, London, recognized for his contributions to Biomedical Sciences. He currently serves as Vice-Chancellor of Maharaja Surajmal Brij University, Rajasthan, and is the Founder Director of the Dr. B. R. Ambedkar Center for Biomedical Research at the University of Delhi. Prof. Chandra has held prominent positions including Vice-Chancellor of Bundelkhand University and Head of the Department of Chemistry at the University of Delhi. He has also served as an official resource person to the Minister and Department of Science and Technology in Lesotho, South Africa. His research career spans prestigious institutions such as Cornell University, Rockefeller University, Harvard Medical School, and MIT. He started his research career at the University of Delhi, then at The New York Hospital-Cornell University Medical College, and The Rockefeller University, New York; State University of New York at Stony brook, New York; Harvard University Medical School-Massachusetts General Hospital (MGH) jointly at MIT, Cambridge, MA, USA. Prof. Chandra has been Vice-Chancellor, Bundelkhand University, Jhansi (1999-2005) as well as President of the Indian Chemical Society, Member, Planning Commission, Government of U.P. India; Secretary - Zaheer Science Foundation, New Delhi and Non-Official Director, Rashtriya Ispat Nigam Ltd, Government of India. He was also Head of the Department of Chemistry, University of Delhi. He is recipient of several international recognitions: J. William Fulbright Scholarship, The Rockefeller Foundation USA-Biotechnology Career Award, Award of the Highest Honor of Soka University, Tokyo, Japan; Millennium Plaques of Honor (Life Time Achievement Award for contribution in Science & Technology) by the Indian Science Congress Association (ISCA), Lifetime Achievement Award of the Indian Chemical Society (ICS); UGC Research Scientist Award; UGC Career Award; Rajib Goyal Award for Young Scientists and others. Prof. Chandra shows deep commitment to the cause of higher education & research and possesses in ample measure quality of dynamic leadership, vision required for building academic institutions and excelled in his academic pursuits. To illustrate, he has to his credit several international patents, 9 Books; 28 Book Chapters; and more than 387 original Scientific Research Papers in International journals of repute. He has mentored more than 100 Ph.D students.

1. Ankita , Dadwal
2. Vikas , Jindal
3. Rupinder , Kaur

Porphyromonas Gingivalis - Un PATHOGÈNE DE PIERRE CLÉ

Les maladies parodontales sont des infections multifactorielles provoquées par des espèces bactériennes complexes qui interagissent avec les tissus et les cellules de l'hôte, dont certaines entraînent la destruction des structures parodontales, y compris les tissus de soutien de la dent, l'os alvéolaire et le ligament parodontal. Le déclencheur de la maladie est la présence d'un biofilm microbien complexe qui colonise les régions sulculaires entre la surface de la dent et la marge gingivale par le biais d'interactions d'adhérence spécifiques et d'une accumulation due à des changements architecturaux dans le sulcus. Porphyromonas gingivalis est l'espèce la plus fortement associée à la forme chronique de la parodontite, et peut être détectée jusqu'à 85% des sites de la maladie. La capacité de P. gingivalis à moduler la cascade inflammatoire immunitaire de l'hôte en inhibant l'IL-8 des cellules épithéliales gingivales en fait un pathogène clé dans l'orchestration de la réponse de l'hôte. D'autres recherches sont en cours pour étudier l'utilisation de ces antigènes en tant que candidats vaccins qui, s'ils sont utilisés de manière appropriée, pourraient servir de thérapie d'appoint pour améliorer la parodontite chronique.

1. Ankita , Dadwal
2. Vikas , Dzhindal
3. Rupinder , Kaur

Porphyromonas Gingivalis - klüchewoj patogen kamnq

Zabolewaniq parodonta - äto mnogofaktornye infekcii, wyzywaemye slozhnymi widami bakterij, kotorye wzaimodejstwuüt s tkanqmi i kletkami hozqina, nekotorye iz nih priwodqt k razrusheniü struktur parodonta, wklüchaq opornye tkani zuba, al'weolqrnuü kost' i parodontal'nuü swqzku. Puskowym mehanizmom dlq nachala zabolewaniq qwlqetsq nalichie slozhnoj mikrobnoj bioplenki, kotoraq koloniziruet sul'ku mezhdu powerhnost'ü zuba i desnoj cherez specificheskie adgeziwnye wzaimodejstwiq i nakapliwaetsq w rezul'tate arhitekturnyh izmenenij w sul'ke. Porphyromonas gingivalis qwlqetsq widom, naibolee sil'no associirowannym s hronicheskoj formoj parodontita, i mozhet byt' obnaruzhen w 85 % sluchaew zabolewaniq. Sposobnost' P. gingivalis modulirowat' immunnyj wospalitel'nyj kaskad hozqina putem ingibirowaniq IL-8 äpitelial'nymi kletkami desny rassmatriwaet ego kak klüchewoj patogen w orkestrowke otweta hozqina. Prodolzhaütsq issledowaniq po izucheniü ispol'zowaniq ätih antigenow w kachestwe kandidatow w wakciny, kotorye pri prawil'nom primenenii mogut byt' polezny w kachestwe dopolnitel'noj terapii dlq oblegcheniq hronicheskogo periodontita.

1. Ankita , Dadwal
2. Vikas , Jindal
3. Rupinder , Kaur

Porphyromonas Gingivalis - EIN SCHLÜSSELSTEIN-PATHOGEN

Parodontalerkrankungen sind multifaktorielle Infektionen, die durch eine komplexe Bakterienspezies ausgelöst werden, die mit den Geweben und Zellen des Wirts interagieren und in einigen Fällen zur Zerstörung der parodontalen Strukturen, einschließlich des Zahnhaltegewebes, des Alveolarknochens und des parodontalen Ligaments führen. Auslöser der Erkrankung ist das Vorhandensein eines komplexen mikrobiellen Biofilms, der die Sulkusbereiche zwischen der Zahnoberfläche und dem Zahnfleischrand durch spezifische Adhärenzinteraktionen und Akkumulation aufgrund architektonischer Veränderungen im Sulkus besiedelt. Porphyromonas gingivalis ist die Spezies, die am stärksten mit der chronischen Form der Parodontitis assoziiert ist, und kann in bis zu 85 % der Krankheitsherde nachgewiesen werden. Die Fähigkeit von P. gingivalis, die immunologische Entzündungskaskade des Wirts zu modulieren, indem er IL-8 aus den Epithelzellen der Gingiva hemmt, macht ihn zum Schlüsselerreger bei der Orchestrierung der Wirtsreaktion. Es wird weiter geforscht, um die Verwendung dieser Antigene als Impfstoffkandidaten zu untersuchen, die, wenn sie richtig eingesetzt werden, als ergänzende Therapie zur Verbesserung der chronischen Parodontitis nützlich sein könnten.

1. Ankita , Dadwal
2. Vikas , Jindal
3. Rupinder , Kaur

Porphyromonas Gingivalis - UN PATOGENO CHIAVE DI STUDIO

Le malattie parodontali sono infezioni multifattoriali provocate da specie batteriche complesse che interagiscono con i tessuti e le cellule dell'ospite, alcune delle quali portano alla distruzione delle strutture parodontali, compresi i tessuti di sostegno del dente, l'osso alveolare e il legamento parodontale. Il fattore scatenante dell'inizio della malattia è la presenza di biofilm microbici complessi che colonizzano le regioni sulculari tra la superficie del dente e il margine gengivale attraverso specifiche interazioni di adesione e l'accumulo dovuto a cambiamenti architettonici nel solco. Porphyromonas gingivalis è la specie maggiormente associata alla forma cronica di parodontite e può essere rilevata fino all'85% dei siti di malattia. La capacità di P. gingivalis di modulare la cascata immunitaria infiammatoria dell'ospite inibendo l'IL-8 dalle cellule epiteliali gengivali lo rende un patogeno chiave nell'orchestrare la risposta dell'ospite. Sono in corso ulteriori ricerche per studiare l'uso di questi antigeni come candidati vaccini che, se utilizzati in modo appropriato, potrebbero essere utili come terapia aggiuntiva per migliorare la parodontite cronica.

1. Ankita , Dadwal
2. Vikas , Jindal
3. Rupinder , Kaur

Porphyromonas Gingivalis - UM PATOGÉNIO DE PEDRA-CHAVE

As doenças periodontais são infecções multifactoriais provocadas por uma espécie bacteriana complexa que interage com os tecidos e células do hospedeiro, algumas das quais levam à destruição das estruturas periodontais, incluindo os tecidos de suporte dos dentes, o osso alveolar e o ligamento periodontal. O gatilho para o início da doença é a presença de biofilme microbiano complexo que coloniza as regiões sulculares entre a superfície do dente e a margem gengival através de interacções de adesão específicas e acumulação devido a alterações arquitectónicas no sulco. A Porphyromonas gingivalis é a espécie mais associada à forma crónica da periodontite, podendo ser detectada em até 85% dos locais de doença. A capacidade da P. gingivalis para modular a cascata inflamatória imune do hospedeiro através da inibição da IL-8 das células epiteliais gengivais considera-a como um agente patogénico fundamental na orquestração de uma resposta do hospedeiro. Está em curso mais investigação para estudar a utilização destes antigénios como vacinas candidatas, que, se utilizadas adequadamente, podem ter utilidade como terapia adjuvante na melhoria da periodontite crónica.